Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2
Authors
Keywords
antiviral, entry, coronavirus, TMPRSS2, cyclosporin, cyclophilin, screening, HTS, drugs, SARS2
Journal
Cell Reports
Volume 35, Issue 1, Pages 108959
Publisher
Elsevier BV
Online
2021-03-24
DOI
10.1016/j.celrep.2021.108959
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
- (2021) Emma S. Winkler et al. CELL
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
- (2020) Manli Wang et al. CELL RESEARCH
- A new coronavirus associated with human respiratory disease in China
- (2020) Fan Wu et al. NATURE
- Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody
- (2020) Xiaolong Tian et al. Emerging Microbes & Infections
- Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
- (2020) Michael Letko et al. Nature Microbiology
- Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
- (2020) Sangeun Jeon et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract
- (2020) Yixuan J. Hou et al. CELL
- Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
- (2020) Daniel Blanco-Melo et al. CELL
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model
- (2020) Hua-Hao Fan et al. CHINESE MEDICAL JOURNAL
- IL-6: Relevance for immunopathology of SARS-CoV-2
- (2020) E.O. Gubernatorova et al. CYTOKINE & GROWTH FACTOR REVIEWS
- COVID-19 and Calcineurin Inhibitors: Should They Get Left Out in the Storm?
- (2020) Michelle Willicombe et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cell entry mechanisms of SARS-CoV-2
- (2020) Jian Shang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells
- (2020) Shutoku Matsuyama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cytokine release syndrome in severe COVID-19
- (2020) John B. Moore et al. SCIENCE
- An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
- (2020) Timothy P. Sheahan et al. Science Translational Medicine
- Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
- (2020) Xiuyuan Ou et al. Nature Communications
- Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro
- (2020) Jia Liu et al. Cell Discovery
- COVID-19 Pandemic: Time to Revive the Cyclophilin Inhibitor Alisporivir
- (2020) Jean-Michel Pawlotsky CLINICAL INFECTIOUS DISEASES
- A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
- (2020) David R. Boulware et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ongoing Clinical Trials for the Management of the COVID-19 Pandemic
- (2020) Mark P. Lythgoe et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Potential Antiviral Options against SARS-CoV-2 Infection
- (2020) Aleksandr Ianevski et al. Viruses-Basel
- Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements
- (2020) Abhjieet Pandey et al. LIFE SCIENCES
- Genetic mechanisms of critical illness in Covid-19
- (2020) Erola Pairo-Castineira et al. NATURE
- Salinomycin triggers endoplasmic reticulum stress through ATP2A3 upregulation in PC-3 cells
- (2019) Yunsheng Zhang et al. BMC CANCER
- Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization
- (2019) Masashi Iwamoto et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cepharanthine: An update of its mode of action, pharmacological properties and medical applications
- (2019) Christian Bailly PHYTOMEDICINE
- Derivation of self-renewing lung alveolar epithelial type II cells from human pluripotent stem cells
- (2019) Anjali Jacob et al. Nature Protocols
- Natural Bis-Benzylisoquinoline Alkaloids-Tetrandrine, Fangchinoline, and Cepharanthine, Inhibit Human Coronavirus OC43 Infection of MRC-5 Human Lung Cells
- (2019) Kim et al. Biomolecules
- Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication
- (2019) Yue Ma-Lauer et al. ANTIVIRAL RESEARCH
- Salinomycin, as an autophagy modulator-- a new avenue to anticancer: a review
- (2018) Jiang Jiang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells
- (2018) Jean Kaoru Millet et al. VIROLOGY
- Epidermal growth factor receptor is a co-factor for transmissible gastroenteritis virus entry
- (2018) Weiwei Hu et al. VIROLOGY
- Targeting the Ca2+/Calmodulin-dependent protein kinase II by Tetrandrine in human liver cancer cells
- (2018) Tracy Huang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Salinomycin Inhibits Influenza Virus Infection by Disrupting Endosomal Acidification and Viral Matrix Protein 2 Function
- (2018) Yejin Jang et al. JOURNAL OF VIROLOGY
- Drug repurposing: progress, challenges and recommendations
- (2018) Sudeep Pushpakom et al. NATURE REVIEWS DRUG DISCOVERY
- Origin and evolution of pathogenic coronaviruses
- (2018) Jie Cui et al. NATURE REVIEWS MICROBIOLOGY
- Feline coronavirus replication is affected by both cyclophilin A and cyclophilin B
- (2017) Yoshikazu Tanaka et al. JOURNAL OF GENERAL VIROLOGY
- Screening Bioactives Reveals Nanchangmycin as a Broad Spectrum Antiviral Active against Zika Virus
- (2017) Keiko Rausch et al. Cell Reports
- Axl Mediates ZIKA Virus Entry in Human Glial Cells and Modulates Innate Immune Responses
- (2017) Laurent Meertens et al. Cell Reports
- Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
- (2016) Travis K. Warren et al. NATURE
- SARS and MERS: recent insights into emerging coronaviruses
- (2016) Emmie de Wit et al. NATURE REVIEWS MICROBIOLOGY
- Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment
- (2015) Yasuteru Sakurai et al. SCIENCE
- Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis
- (2015) Jean Kaoru Millet et al. VIRUS RESEARCH
- Genetic deficiency and polymorphisms of cyclophilin A reveal its essential role for Human Coronavirus 229E replication
- (2015) Albrecht von Brunn et al. Current Opinion in Virology
- Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection
- (2014) Julie Dyall et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cyclophilin inhibition as potential therapy for liver diseases
- (2014) Nikolai V. Naoumov JOURNAL OF HEPATOLOGY
- Viruses exploit the function of epidermal growth factor receptor
- (2014) Kai Zheng et al. REVIEWS IN MEDICAL VIROLOGY
- Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir
- (2014) Javier Carbajo-Lozoya et al. VIRUS RESEARCH
- Salinomycin induces activation of autophagy, mitophagy and affects mitochondrial polarity: Differences between primary and cancer cells
- (2013) Jaganmohan Reddy Jangamreddy et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon- treatment
- (2013) A. H. de Wilde et al. JOURNAL OF GENERAL VIROLOGY
- Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486
- (2013) B. M. Dolan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cyclophilin A and viral infections
- (2012) Daijun Zhou et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Hepatocytes That Express Variants of Cyclophilin A Are Resistant to HCV Infection and Replication
- (2012) Thomas von Hahn et al. GASTROENTEROLOGY
- Severe Acute Respiratory Syndrome Coronavirus Replication Is Severely Impaired by MG132 due to Proteasome-Independent Inhibition of M-Calpain
- (2012) Martha Schneider et al. JOURNAL OF VIROLOGY
- Hepatitis C Virus Induces Epidermal Growth Factor Receptor Activation via CD81 Binding for Viral Internalization and Entry
- (2012) J. Diao et al. JOURNAL OF VIROLOGY
- Cyclophilin A Restricts Influenza A Virus Replication through Degradation of the M1 Protein
- (2012) Xiaoling Liu et al. PLoS One
- Cyclosporin A Inhibits the Influenza Virus Replication through Cyclophilin A-Dependent and -Independent Pathways
- (2012) Xiaoling Liu et al. PLoS One
- Salinomycin Induces Autophagy in Colon and Breast Cancer Cells with Concomitant Generation of Reactive Oxygen Species
- (2012) Berlinda Verdoodt et al. PLoS One
- Cyclosporin A inhibits the replication of diverse coronaviruses
- (2011) A. H. de Wilde et al. JOURNAL OF GENERAL VIROLOGY
- Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune Response
- (2011) I. Glowacka et al. JOURNAL OF VIROLOGY
- Chicken cyclophilin A is an inhibitory factor to influenza virus replication
- (2011) Chongfeng Xu et al. Virology Journal
- R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer
- (2010) S. J. Holland et al. CANCER RESEARCH
- Hepatitis B Virus (HBV) Surface Antigen Interacts with and Promotes Cyclophilin A Secretion: Possible Link to Pathogenesis of HBV Infection
- (2010) X. Tian et al. JOURNAL OF VIROLOGY
- An emerging role for p21-activated kinases (Paks) in viral infections
- (2010) Celine Van den Broeke et al. TRENDS IN CELL BIOLOGY
- The Epidermal Growth Factor Receptor (EGFR) Promotes Uptake of Influenza A Viruses (IAV) into Host Cells
- (2010) Thorsten Eierhoff et al. PLoS Pathogens
- Histamine H1-receptor antagonists with immunomodulating activities: potential use for modulating T helper type 1 (Th1)/Th2 cytokine imbalance and inflammatory responses in allergic diseases
- (2009) T. Okamoto et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Thiosemicarbazones from the Old to New: Iron Chelators That Are More Than Just Ribonucleotide Reductase Inhibitors
- (2009) Yu Yu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites
- (2009) S. Belouzard et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Differential effects of triptolide and tetrandrine on activation of COX-2, NF-κB, and AP-1 and virus production in dengue virus-infected human lung cells
- (2008) Jun-Ting Liou et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Cyclophilin A Is an Essential Cofactor for Hepatitis C Virus Infection and the Principal Mediator of Cyclosporine Resistance In Vitro
- (2008) F. Yang et al. JOURNAL OF VIROLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now